Methods We administered 0.5 mg of entecavir once daily for more than 12 months to 114
naive chronic hepatitis B (CHB) patients. We measured the levels of liver enzymes …

Methods A total of 160 patients treated with entecavir (0.5 mg daily) for at least 24 weeks
were consecutively enrolled. The virologic response (HBV DNA< 2,000 copies/mL) …

BACKGROUND & AIMS: To evaluate the long-term efficacy of entecavir in nucleoside-naïve
chronic hepatitis B patients. METHODS: One hundred and sixty-seven patients treated with …

Abstract Background and Aim: Entecavir has demonstrated clinical efficacy for chronic
hepatitis B. This study evaluated the efficacy and safety of entecavir in nucleoside‐naive …

Objective To evaluate the efficacy of entecavir treatment up to 96 weeks for patients with
chronic hepatitis B (CHB). Methods The study recruited 62 CHB patients who were admitted …

Methods One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were
evaluated for cumulative rates of virologic response, biochemical response, and entecavir …

Background Entecavir is an effective treatment for chronic hepatitis B. However, data from
clinical practice are limited, especially in hepatitis B e antigen (HBeAg)-positive patients …

Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis
B in the short term, but its long term efficacy and safety has not been established. Material …

Objective As the efficacy of a direct antiviral agent is reduced in cirrhotic chronic hepatitis C
patients, prolonged duration of treatment or addition of ribavirin is recommended to improve …

Abstract Background and Aim Although entecavir has been shown to have good efficacy
and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a …